Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic Bridging and DDI Study of Risvodetinib in Healthy Older Adults
NCT06644326Phase 1Completed
- Sponsor
- ABLi Therapeutics, Inc.
- Start
- Jun 2023
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of risvodetinib in Parkinson's disease (PD) (2 arms), sponsored by ABLi Therapeutics, Inc. Primary endpoints: Patient Safety, Pharmacokinetic parameters and 1 more. Started Jun 2023; status: completed.
02
Drugs
risvodetinib
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT06644326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06644326.